Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Reexamination Certificate
2006-10-17
2006-10-17
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
Reexamination Certificate
active
07122576
ABSTRACT:
This invention is directed to a method for preventing or treating bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates:wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3and R4are independently selected from the group consisting of hydrogen and C1–C4alkyl; wherein C1–C4alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1–C4alkyl, C1–C4alkoxy, amino, nitro and cyano).
REFERENCES:
patent: 3265728 (1966-08-01), Bossinger et al.
patent: 3278380 (1966-10-01), Bossinger et al.
patent: 3313692 (1967-04-01), Bossinger et al.
patent: 5698588 (1997-12-01), Choi et al.
patent: 5854283 (1998-12-01), Choi et al.
patent: 6103759 (2000-08-01), Choi et al.
patent: 6127412 (2000-10-01), Choi et al.
U.S. Appl. No. 09/906,251, Ortho-McNeil Pharmaceutical, Inc.
U.S. Appl. No. 10/081,764, Ortho-McNeil Pharmaceutical, Inc.
U.S. Appl. No. 10/081,501, Ortho-McNeil Pharmaceutical, Inc.
U.S. Appl. No. 10/081,943, Ortho-McNeil Phamaceutical, Inc.
U.S. Appl. No. 10/081,766, Ortho-McNeil Pharmaceutical, Inc.
U.S. Appl. No. 10/081,761, Ortho-McNeil Pharmaceutical, Inc.
U.S. Appl. No. 10/081,713, Ortho-McNeil Pharmaceutical, Inc.
U.S. Appl. No. 10/193,600, Ortho-McNeil Pharmaceutical, Inc.
U.S. Appl. No. 10/192,973, Ortho-McNeil Pharmaceutical, Inc.
International PCT Search Report PCT/US02/05541 dated Jul. 8, 2002.
Akisakl, H.S., et al.,Re-evaluatiang the Prevalence of and Diagnostic Composition Within the Broad Clinical Spectrum of Bipolar Disorders,J. Affect. Disord., 2000, 59 (*Suppl 1), S5-S30.
Goodwin, F., et al.,Manic-Depressive Illness,Oxford University Press, New York, 1990, pp 405-407.
Ghaemi, S.N., et al.,Kindling and Second Messengers: An Approach to the Neurobiology of Recurrence in Bipolar Disorder,Biol. Psychiatry, 1999, 45(2) 137-144.
Stoll, A.L., et al.,Mood Stabilizers: Shared Mechanisms of Action at Postsynaptic Signal-Transduction and Kindling Processes, Harv. Rev. Psychiatry, 1996, 4(2),77-89.
Janowsky, D.S.New Treatments of Bipolar Disorder,Curr. Psychiatry Rep., 1999 1(2), 111-113.
Shelton, M.D., et al.,Current Concepts in Rapid Cycling Bipolar Disorder,Curr. Psychiatry Rep., 2000, 2(4), 310-315.
Lennkh, C., et al.,Current Aspects of Valproate in Bipolar Disorder,Int. Clin. Psychopharmacol., 2000, 15(1), 1-11.
Tohen, M., et al.,Management of Acute Mania,J. Clin. Psuchiatry, 1999, 60, (Suppl 5) 31-34.
Muller-Oerlinghausen, B., et al.,Valproate as an Adjunct to Neuroleptic Medication for the Treatment of Acute Episodes of Mania: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study,European Valproate Mania Study Group, J. Clin. Psychopharmacol., 2000 20(2), 195-203.
Sachs, G.S., et al.,The Expert Consensus Guideline Series, Medication Treatment of Bipolar Disorder 2000,Postgrad. Med., 2000, Spec No: 1-104.
Bipolar Disorder,Cognos Study #53, Decision Resources, Mar. 2000.
Wauquier, A., et al.,Topiramate: A Potent Anticonvulsant in the Amygdala-Kindled Rat,Epilepsy Res., 1996, 24, 73-77.
Goldberg, J.F., et al.,Kindling in Bipolar Disorders: A Longitudinal Follow-up Study,Biol. Psychiatry, 1994, 1; 35(1), 70-72.
Sadock, B.J., et al.,Treatment of Bipolar Disorders,Comprehensive Textbook of Psychiatry, 2000, vol. 1, 1385-1430.
Post, R.M., et al.,A History of the Use of Anticonvulsants as Mood Stabilizers in the Last Two Decades of the 20thCentury,Neuropsychobiology, Abstract, 1998, 38(3), 152-166.
Diagnostic and Statistical Manual of Mental Disorders, Edition 4, American Psychiatric Association, Washington, D.C., 1994.
Lothman et al, “Screening and Characterization of Antiepileptic Drugs with Rapidly Recurring Hippocampal Seizures in Rats”,Epilepsy Res.,vol. 2, No. 6, pp 367-379 (Nov.-Dec. 1988).
Morozova MA, “The new approaches to treatment of depression at bipolar affective disorders,” 2001 Psikhiatriya I Psikhofarmakologiya 3(1): 1-8; translation from Russian.
Post et al., “A History of the Use of Anticonvulsants as Mood Stabilizers in the Last Two Decades of the 20thCentury”, Neuropsychobiology (1988), vol. 38, pp. 152-166.
Choi Yong Moon
Gordon Robert
Plata-Salaman Carlos R.
Twyman Roy E.
Zhao Boyu
Lewis Amy A.
Low Christopher S. F.
LandOfFree
Carbamate compounds for use in preventing or treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbamate compounds for use in preventing or treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbamate compounds for use in preventing or treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3708792